Skip to main content

Affibody AB and Amylin Pharmaceuticals, Inc. enter into A License Agreement regarding the Albumod™ platform

Pressmeddelande   •   Okt 05, 2010 14:40 CEST

Affibody AB and Amylin Pharmaceuticals, Inc. have signed a License Agreement regarding the use of Affibody’s proprietary Albumod™ platform which is designed to enhance the efficacy of biopharmaceuticals by extending their circulatory half-life. The technology will be applied on an undisclosed number of molecules from Amylin’s library of proprietary compounds. Affibody will receive up-front and milestone payments as well as royalties on sales for licensing of the Albumod™ platform. Further details of the agreement have not been disclosed.

About the Albumod™ platform

Affibody’s Albumod™ technology is designed to enhance the efficacy of biopharmaceuticals by extending their circulatory half-life, potentially allowing for less frequent dosing and lower peak concentrations in blood with a decreased risk for adverse events. Furthermore, the Albumod™ technology may potentially be used to evade an immune response. In addition to these possible patient safety benefits, the overall treatment costs may be reduced.

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Affibody is developing a portfolio of innovative drug projects and, in addition, offers the half-life extension technology, Albumod™, for outlicensing.

Affibody has ongoing commercial relationships with several companies including Algeta, Amylin, Swedish Orphan Biovitrum, GE, and Thermo Fisher.

Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden. Major shareholders in the Company include HealthCap and Investor Growth Capital.

Further information can be found at: